跳至主要内容
临床试验/PACTR202305854600529
PACTR202305854600529已完成3 期

Evaluating the Outcomes and Tolerability of Adding Local Radical Prostate Radiotherapy to the Standard of Care in Metastatic Prostate Cancer Patients

Suez Canal University0 个研究点目标入组 50 人开始时间: 2023年4月27日最近更新:
适应症

试验速览

阶段
3 期
状态
已完成
入组人数
50

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
65 Year(s) 至 150 Year(s)(—)
性别
Male

入选标准

  • Patients diagnosed with metastatic prostate cancer who were receiving standard of care,
  • androgen deprivation therapy and were:
  • Patients scored performance status 0-2 according to Eastern Cooperative Oncology
  • Group (ECOG) performance scale.
  • Histologically proven adenocarcinoma of the prostate.
  • De-novo (synchronous) and metachronous metastatic prostate cancer patients.
  • Low volume metastatic prostate cancer (< 4 bone metastases) according to CHAARTED
  • definition.
  • High-volume metastatic prostate cancer (= 4 bone metastases at least 1 beyond spine
  • or pelvis, ± visceral metastases) according to CHAARETED definition.
  • No previous radical prostatectomy.
  • With or without nodal involvement.
  • Adequate hematological profile; Hemoglobin = 10.0 g/dl, neutrophil count =1500
  • cells/mm3 and platelets =100000/mL before the start of treatment.
  • Written informed consent.

排除标准

  • Patients scored PS > 2 according to ECOG performance scale.
  • Presence of other diagnosed malignancies
  • Previous radical prostatectomy.
  • Previous local prostate radiotherapy or brachytherapy.
  • Presence of brain metastases or leptomeningeal metastases.

研究者

相似试验